Objective To explore the effects of childhood abuse on leptin level in blood plasma of adult depression patients.Methods 106 depression patients were included in this study.Children abuse status,severity of depression anxiety were assessed with the childhood trauma questionnaire (CTQ),Hamil-ton rating scale for depression ( HAMD) and Hamilton rating scale for anxiety ( HAMA) .According to CTQ score subjects were divided into abuse group ( n=38) and non-abuse group ( n=68) .Leptin levels were de-termined using the Enzyme Linked Immunosorbent Assay.Results Of 106 depression patients 35.85%( n=38) had been abused in childhood according to the result of CTQ score.There were significant differences between the abuse group and the non-abuse group in the age of first onset,sex ratio,the total score of the HAMD-24,the total score of HAMA.Leptin level of abuse group ((4.989±2.820)μg/L) was lower than that in non-abuse group((7.324±4.941)μg/L, P<0.05) and control group ((9.811±7.353)μg/L, P<0.01).Leptin level in non-abuse group was lower than that in control group ( P<0.01).Conclusion Childhood abuse obviously influences lep-tin levels of adult depression patients,which may be a risk factor of adult depression development.

Objective To evaluate the efficacy of metformin on liver fat content in schizophrenia patients with olanzapine-induced weight gain, and the relationship between the change of LFC and the other metabolic indices. Methods In a double-blind study, the clinically stable inpatients with first-episode schizophrenia under olanzapine monotherapy who gained more than 7% of their baseline weight were randomly assigned to two groups, one with olanzapine plus metformin (1 000 mg/d) (metformin group), the other with olanzapine plus placebo(placebo group) for 16 weeks. All patients continued to maintain the original olanzapine dosage. Liver fat content was measured by MRI at baseline and at the end of 16 weeks, respectively. At the same time, glucose and lipid metabolism (including fasting blood glucose, hemoglobin A1c, total cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein-cholesterol), homeostasis model assessment of insulin resistance index were measured respectively, analysing the correlation between the change value of LFC and other indicators. Results (1)Over the 16-week study period, LFC value in metformin group decreased compared with baseline ((16.55 ± 7.51)% vs.(19.47 ± 8.99)%, t=2.909,P<0.05).LFC change across the 16-week treatment period was-2.91%for the metformin group and 0.59%for the placebo group, with a between-group difference of-3.5%(95%CI=-6.08 to-0.93, P=0.009). (2) Compared to baseline, in the metformin group, triglyceride and HOMA-IR reduced significantly, while high density lipoprotein cholesterol increased significantly at weeks 16(t=2.242, 2.116, 3.226, all P<0.05).(3)There was positive correlation between LFC changes and TG,HOMA-IR changes significantly(r=0.505,0.578,both P<0.05).Conclusion Metformin can significantly attenuate liver fat content in schizophrenia patients with olanzapine-induced weight gain. It may be related to the improvement of the part of the glucolipid metabolic indices.

Objective To evaluate the efficacy of metformin on liver fat content in schizophrenia patients with olanzapine-induced weight gain, and the relationship between the change of LFC and the other metabolic indices. Methods In a double-blind study, the clinically stable inpatients with first-episode schizophrenia under olanzapine monotherapy who gained more than 7% of their baseline weight were randomly assigned to two groups, one with olanzapine plus metformin (1 000 mg/d) (metformin group), the other with olanzapine plus placebo(placebo group) for 16 weeks. All patients continued to maintain the original olanzapine dosage. Liver fat content was measured by MRI at baseline and at the end of 16 weeks, respectively. At the same time, glucose and lipid metabolism (including fasting blood glucose, hemoglobin A1c, total cholesterol, triglycerides, high density lipoprotein cholesterol, low density lipoprotein-cholesterol), homeostasis model assessment of insulin resistance index were measured respectively, analysing the correlation between the change value of LFC and other indicators. Results (1)Over the 16-week study period, LFC value in metformin group decreased compared with baseline ((16.55 ± 7.51)% vs.(19.47 ± 8.99)%, t=2.909,P<0.05).LFC change across the 16-week treatment period was-2.91%for the metformin group and 0.59%for the placebo group, with a between-group difference of-3.5%(95%CI=-6.08 to-0.93, P=0.009). (2) Compared to baseline, in the metformin group, triglyceride and HOMA-IR reduced significantly, while high density lipoprotein cholesterol increased significantly at weeks 16(t=2.242, 2.116, 3.226, all P<0.05).(3)There was positive correlation between LFC changes and TG,HOMA-IR changes significantly(r=0.505,0.578,both P<0.05).Conclusion Metformin can significantly attenuate liver fat content in schizophrenia patients with olanzapine-induced weight gain. It may be related to the improvement of the part of the glucolipid metabolic indices.